Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131 Group","sponsor":"PharmaMar","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar Signs a New Licensing and Commercialization Agreement With Eczacibasi for Lurbinectedin in Turkey","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"TURKEY","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","sponsor":"FutureChem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monrol and FutureChem Announced a Clinical Supply Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"TURKEY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Eczacıbaşı Group

    Menu

    Eczacıbaşı Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Eczacıbaşı-Monrol Nuclear Products

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Turkey
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Monrol and FutureChem Announced a Clinical Supply Partnership

              Details:

              177Lu-FC705 belongs to the 2nd generation of albumin binders introduced drugs. Its hydrophilicity is higher than that of other compounds, and has low nonspecific binding.

              Lead Product(s): [177Lu]Ludotadipep

              Therapeutic Area: Oncology Product Name: 177Lu-FC705

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: FutureChem

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership November 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eczacıbaşı Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Turkey
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmaMar Signs a New Licensing and Commercialization Agreement With Eczacibasi for Lurbinectedin in Turkey

              Details:

              Eczacıbaşı will pursue the marketing authorization in Turkey and will have the right to commercialize the Zepzelca (Lurbinectedin), on an exclusive basis, upon approval. Lurbinectedin was granted accelerated approval by FDA for relapsed metastatic Small Cell Lung Cancer.

              Lead Product(s): Lurbinectedin

              Therapeutic Area: Oncology Product Name: Zepzelca

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: PharmaMar

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement December 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY